When you fill a prescription or purchase an over-the-counter medication, you place your trust in the pharmaceutical manufacturers who design, test, and market these products. Under corporate product liability laws, drug manufacturers hold a strict legal obligation to ensure their products are reasonably safe and to provide explicit, comprehensive disclosures regarding all known severe risks. When corporations fail in this duty, legal claims typically fall into three distinct categories:

• Failure to Warn (Marketing Defects): This occurs when a drug company knows or should have known about a dangerous side effect but intentionally minimizes or omits that information from the drug’s warning label. A classic example is a pharmaceutical failure to warn case, where a warning label notes generic “vision changes” but fails to warn physicians that a medication can cause permanent blindness.
• Design Defects: Claims alleging that a medication’s inherent chemical formulation makes it unreasonably dangerous for its intended use, meaning the health risks fundamentally outweigh the drug’s therapeutic benefits.
• Manufacturing Defects: Incidents where a drug becomes contaminated or compromised during the physical production, packaging, or distribution phases, deviating from its intended design.

Even if a medication has received formal approval from the U.S. Food and Drug Administration (FDA), drug makers are not shielded from liability. Under civil law, regulatory approval represents a baseline safety standard, not an absolute defense against corporate negligence or the withholding of critical post-market adverse event data.